Finally, the TRIO-012 trial included 153 patients with advanced HER2 negative breast cancer who received beta-blockers (n = 13, propranolol) with 71% of total patients receiving them as an adjunct to ramucirumab (Spera et al. 2017). The gene discussed is ERBB2; the disease is breast cancer.